{"id":9638,"date":"2023-04-30T15:37:34","date_gmt":"2023-04-30T12:37:34","guid":{"rendered":"https:\/\/kenes-exhibitions.com\/biomed\/?p=9638"},"modified":"2023-04-30T15:39:32","modified_gmt":"2023-04-30T12:39:32","slug":"novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8","status":"publish","type":"post","link":"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/","title":{"rendered":"Novel Alliance Responds to Big Pharma&#8217;s Most Pressing AI\/ML Needs (Feb 8)"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"9638\" class=\"elementor elementor-9638\">\n\t\t\t\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-b1fb203 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"b1fb203\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1a3eec8\" data-id=\"1a3eec8\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ac6a182 elementor-widget elementor-widget-text-editor\" data-id=\"ac6a182\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.12.1 - 02-04-2023 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<div class=\"block article-meta\"><p><span class=\"palm-block-level\">Published: Feb 08, 2023<\/span>\u00a0<span class=\"palm-block-level\">By Heather McKenzie<\/span><\/p><\/div><div class=\"block fix-text js-fitvid\"><p><img src=\"https:\/\/admin.biospace.com\/getasset\/cf145783-60c0-47ec-a06f-b6005ac8870d\/?&amp;Test=Test\" alt=\"Yair Benita_AION Labs\" \/><\/p><p><em>Yair Benita, Ph.D., chief technology officer, AION Labs\/courtesy of Tsipi Haitovsky<\/em><\/p><p>Artificial intelligence and machine learning applications are not the future of drug development; they\u2019re already here, being deployed at large pharmaceutical companies like\u00a0<a href=\"https:\/\/www.biospace.com\/article\/pfizer-doubles-down-on-ai-ml-to-bring-transformative-medicines-to-patients-\/\">Pfizer<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.biospace.com\/employer\/503950\/merck-kgaa-darmstadt-germany\/\">Merck KGaA<\/a>.<\/p><p>For big pharma to truly maximize AI\/ML\u2019s potential, however, better infrastructure is needed. \u00a0<\/p><p>\u201cIf you ask people, &#8216;What do you think drug discovery and development will look like 20 years from now?&#8217; Almost everybody gives you a very digital vision, [where] everything will be simulated,\u201d said Yair Benita, Ph.D., chief technology officer at AION Labs. \u201cNobody says, \u2018I&#8217;m going to have a huge lab with thousands of biologists.\u2019<\/p><p>\u201cBut when you look at what&#8217;s happening in reality, the technology doesn&#8217;t push pharma forward fast enough or well enough. There are many obstacles in bringing technology to pharma.\u201d\u00a0<\/p><p>Benita will lead AI\/ML and pharmaceutical leaders in a brainstorming session at the upcoming\u00a0<a href=\"https:\/\/kenes-exhibitions.com\/biomed\/\">Biomed Israel conference<\/a>, May 16th-18th, entitled \u201cAI tapestry: optimizing the interaction of AI and Biopharma.\u201d<\/p><p>Meanwhile, at AION Labs, Pfizer, AstraZeneca, Merck KgGA and Teva Pharmaceuticals have partnered with the Israel Innovation Authority, Israeli Biotech Fund, Amazon Web Services and Germany\u2019s BioMed X Institute to create and adopt gateway AI and computational technologies for drug discovery and development.\u00a0<\/p><p>Under the model, the pharma companies bring the challenges, and AION launches companies to answer them.<\/p><p><strong>Antibody Design Tops Challenges<\/strong><\/p><p>Recently, AION asked each of its four pharma partners for their top five challenges. Of those, the alliance identified four and invited 15 teams of computational biologics to a boot camp to try to answer them:<\/p><p>1. Develop AI to predict the sequence of a functional antibody for a given protein target.<\/p><p>2. Develop AI to predict clinical trial readiness of drug candidates.<\/p><p>3. Develop software to design and optimize antibodies for targeted therapies.<\/p><p>4. Predict clinical trial outcomes in biomarker-stratified cancer patient populations.<\/p><p>The design of\u00a0<em>de novo<\/em>\u00a0therapeutic antibodies was selected by all as a top priority for the alliance\u2019s first year of operations.<\/p><figure class=\"image\"><img loading=\"lazy\" src=\"https:\/\/www.biospace.com\/getasset\/e778f468-1d1b-4840-a411-b1dc50886a5d\/\" alt=\"Joern-Peter Halle_Merck KgGA\" width=\"200\" height=\"237\" \/><figcaption>Joern-Peter Halle, Ph.D.<\/figcaption><\/figure><p>\u201cIt is very, very difficult to get a good antibody that could make it in the clinic,\u201d said Joern-Peter Halle, Ph.D., chief strategy officer at the Healthcare business of Merck KGaA, Darmstadt, Germany and AION board member.\u00a0<\/p><p>Methodologies developed with DeepMind\u2019s AlphaFold have been a big step forward in analyzing the 3D structure of proteins and identifying attractive therapeutic targets, Halle said.\u00a0<\/p><p>Now, it\u2019s time to enact the second part of that equation, he said, by tweaking the AlphaFold methodologies in a way that will make it possible to identify antibody structures\u00a0<em>in silico<\/em>\u00a0that could enable an antibody to bind to a specific epitope.<\/p><p><strong>Decision Support in Drug Development<\/strong><\/p><p>One of AI\/ML\u2019s greatest potential uses in drug development is R&amp;D decision support. Most mid-to-large biopharma companies have a pipeline made up of several preclinical assets.<\/p><p>\u201cA team that works on a drug is always trying to push their drug forward, but from a management perspective, they&#8217;re risking a lot of company resources,\u201d Benita said. \u201cGoing into clinical trials is a very big decision.\u201d<\/p><p>Despite intensive preclinical research, drug developers\u00a0<a href=\"https:\/\/www.nature.com\/articles\/nrd.2016.184\">failed 25% of the time<\/a>\u00a0on toxicity in humans and 50% on efficacy in Phase II and III clinical trials between 2013 and 2015, according to research published in the journal Nature.<\/p><p>This is where AION\u2019s first startup comes in. The team, which is already in place, is creating a computational platform using AI that can help researchers assess the clinical trial readiness of a drug candidate, identify hidden safety liabilities and suggest experiments to close any identified gaps.<\/p><p>\u201cThe overarching aim is to use AI and machine learning to make our business more productive, more efficient,\u201d Halle said. \u201cWe are going into difficult-to-treat diseases where you have to design clinical trials in a different way.\u201d<\/p><p>Here, AI\/ML applications can assist with the identification of biomarkers.<\/p><p>\u201cIf we just use the standard tools we have used in the past, we will actually go down in terms of productivity,\u201d making more mistakes and losing more time, Halle said. \u201cWe believe using AI will allow us, versus others, to tackle the diseases that are more challenging and more difficult to address.\u201d\u00a0<\/p><p><strong>High-Risk, High-Reward Investment<\/strong><\/p><p>The winners of AION\u2019s boot camp have the opportunity to launch as a startup and receive guidance from mentors within each partnering pharma company.<\/p><p>Once the fledgling company proves its concept, AION and its partners, such as the Israel Innovation Authority, provide the optimal environment to help ensure the success of the venture.\u00a0<\/p><p>An independent public entity funded by the Israeli government, the Israel Innovation Authority (IIA) makes direct investments in applied academic research, startups and growth companies, and national laboratories.<\/p><figure class=\"image\"><img loading=\"lazy\" src=\"https:\/\/www.biospace.com\/getasset\/5a121685-971b-4037-9146-e9875e5b0a61\/\" alt=\"Dror Bin_Israel Innovation Authority\" width=\"200\" height=\"224\" \/><figcaption>Dror Bin<\/figcaption><\/figure><p>Overall, the IIA invests in areas that are \u201cvery risky and not well-funded by the private sector,\u201d said Dror Bin, CEO.\u00a0\u201cWe are looking for the next game-changing, disruptive innovations.\u201d<\/p><p>The Authority also engages with other private and public-sector entities to solve challenges that may hinder growth in the high-tech sector. One of these is the chasm between the high-tech and life sciences ecosystems.<\/p><p>\u201cWe are trying to create [a] fusion between various communities,\u201d Bin said. It\u2019s a concept he calls bio-convergence. \u201cYou need people from life sciences, but you also need computer science and data science experts to develop the artificial intelligence that will do the discovery and development of drugs.\u201d\u00a0<\/p><p>The IIA is heavily invested in AION Labs because \u201cWe believe in what it can create for the ecosystem,\u201d Bin continued.<\/p><p>AION is also an example of IIA\u2019s high-risk investment philosophy, he said. But if it succeeds, \u201cThey\u2019re multipliers of success compared to what we invest.\u201d\u00a0<\/p><p><em>*The Biomed Israel conference facilitated meetings with AION Labs and the Israel Innovation Authority at their labs and offices.<\/em><\/p><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Published: Feb 08, 2023\u00a0By Heather McKenzie Yair Benita, Ph.D., chief technology officer, AION Labs\/courtesy of Tsipi Haitovsky Artificial intelligence and machine learning applications are not the future of drug development; they\u2019re already here, being deployed at large pharmaceutical companies like\u00a0Pfizer\u00a0and\u00a0Merck KGaA. For big pharma to truly maximize AI\/ML\u2019s potential, however, better infrastructure is needed. \u00a0 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":9643,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[14],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.6.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novel Alliance Responds to Big Pharma&#039;s Most Pressing AI\/ML Needs (Feb 8) - Biomed 2026<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novel Alliance Responds to Big Pharma&#039;s Most Pressing AI\/ML Needs (Feb 8) - Biomed 2026\" \/>\n<meta property=\"og:description\" content=\"Published: Feb 08, 2023\u00a0By Heather McKenzie Yair Benita, Ph.D., chief technology officer, AION Labs\/courtesy of Tsipi Haitovsky Artificial intelligence and machine learning applications are not the future of drug development; they\u2019re already here, being deployed at large pharmaceutical companies like\u00a0Pfizer\u00a0and\u00a0Merck KGaA. For big pharma to truly maximize AI\/ML\u2019s potential, however, better infrastructure is needed. \u00a0 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/\" \/>\n<meta property=\"og:site_name\" content=\"Biomed 2026\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-30T12:37:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-30T12:39:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kenes-exhibitions.com\/biomed\/wp-content\/uploads\/2023\/04\/WhatsApp-Image-2023-04-30-at-15.38.13.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"623\" \/>\n\t<meta property=\"og:image:height\" content=\"343\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"chantal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"chantal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/\",\"url\":\"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/\",\"name\":\"Novel Alliance Responds to Big Pharma's Most Pressing AI\/ML Needs (Feb 8) - Biomed 2026\",\"isPartOf\":{\"@id\":\"https:\/\/kenes-exhibitions.com\/biomed\/#website\"},\"datePublished\":\"2023-04-30T12:37:34+00:00\",\"dateModified\":\"2023-04-30T12:39:32+00:00\",\"author\":{\"@id\":\"https:\/\/kenes-exhibitions.com\/biomed\/#\/schema\/person\/bcbdb493d695d393e0f7c5f45999f642\"},\"breadcrumb\":{\"@id\":\"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kenes-exhibitions.com\/biomed\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novel Alliance Responds to Big Pharma&#8217;s Most Pressing AI\/ML Needs (Feb 8)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kenes-exhibitions.com\/biomed\/#website\",\"url\":\"https:\/\/kenes-exhibitions.com\/biomed\/\",\"name\":\"Biomed 2026\",\"description\":\"Biomed 2026 is the largest convention in Israel for Life Sciences and Technology\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kenes-exhibitions.com\/biomed\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/kenes-exhibitions.com\/biomed\/#\/schema\/person\/bcbdb493d695d393e0f7c5f45999f642\",\"name\":\"chantal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kenes-exhibitions.com\/biomed\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/700eefc5df785131a5e93d5e7e21202d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/700eefc5df785131a5e93d5e7e21202d?s=96&d=mm&r=g\",\"caption\":\"chantal\"},\"url\":\"https:\/\/kenes-exhibitions.com\/biomed\/author\/chantal\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novel Alliance Responds to Big Pharma's Most Pressing AI\/ML Needs (Feb 8) - Biomed 2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/","og_locale":"en_US","og_type":"article","og_title":"Novel Alliance Responds to Big Pharma's Most Pressing AI\/ML Needs (Feb 8) - Biomed 2026","og_description":"Published: Feb 08, 2023\u00a0By Heather McKenzie Yair Benita, Ph.D., chief technology officer, AION Labs\/courtesy of Tsipi Haitovsky Artificial intelligence and machine learning applications are not the future of drug development; they\u2019re already here, being deployed at large pharmaceutical companies like\u00a0Pfizer\u00a0and\u00a0Merck KGaA. For big pharma to truly maximize AI\/ML\u2019s potential, however, better infrastructure is needed. \u00a0 [&hellip;]","og_url":"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/","og_site_name":"Biomed 2026","article_published_time":"2023-04-30T12:37:34+00:00","article_modified_time":"2023-04-30T12:39:32+00:00","og_image":[{"width":623,"height":343,"url":"https:\/\/kenes-exhibitions.com\/biomed\/wp-content\/uploads\/2023\/04\/WhatsApp-Image-2023-04-30-at-15.38.13.jpeg","type":"image\/jpeg"}],"author":"chantal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"chantal","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/","url":"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/","name":"Novel Alliance Responds to Big Pharma's Most Pressing AI\/ML Needs (Feb 8) - Biomed 2026","isPartOf":{"@id":"https:\/\/kenes-exhibitions.com\/biomed\/#website"},"datePublished":"2023-04-30T12:37:34+00:00","dateModified":"2023-04-30T12:39:32+00:00","author":{"@id":"https:\/\/kenes-exhibitions.com\/biomed\/#\/schema\/person\/bcbdb493d695d393e0f7c5f45999f642"},"breadcrumb":{"@id":"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/kenes-exhibitions.com\/biomed\/novel-alliance-responds-to-big-pharmas-most-pressing-ai-ml-needs-feb-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kenes-exhibitions.com\/biomed\/"},{"@type":"ListItem","position":2,"name":"Novel Alliance Responds to Big Pharma&#8217;s Most Pressing AI\/ML Needs (Feb 8)"}]},{"@type":"WebSite","@id":"https:\/\/kenes-exhibitions.com\/biomed\/#website","url":"https:\/\/kenes-exhibitions.com\/biomed\/","name":"Biomed 2026","description":"Biomed 2026 is the largest convention in Israel for Life Sciences and Technology","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kenes-exhibitions.com\/biomed\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/kenes-exhibitions.com\/biomed\/#\/schema\/person\/bcbdb493d695d393e0f7c5f45999f642","name":"chantal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kenes-exhibitions.com\/biomed\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/700eefc5df785131a5e93d5e7e21202d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/700eefc5df785131a5e93d5e7e21202d?s=96&d=mm&r=g","caption":"chantal"},"url":"https:\/\/kenes-exhibitions.com\/biomed\/author\/chantal\/"}]}},"_links":{"self":[{"href":"https:\/\/kenes-exhibitions.com\/biomed\/wp-json\/wp\/v2\/posts\/9638"}],"collection":[{"href":"https:\/\/kenes-exhibitions.com\/biomed\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kenes-exhibitions.com\/biomed\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kenes-exhibitions.com\/biomed\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/kenes-exhibitions.com\/biomed\/wp-json\/wp\/v2\/comments?post=9638"}],"version-history":[{"count":4,"href":"https:\/\/kenes-exhibitions.com\/biomed\/wp-json\/wp\/v2\/posts\/9638\/revisions"}],"predecessor-version":[{"id":9646,"href":"https:\/\/kenes-exhibitions.com\/biomed\/wp-json\/wp\/v2\/posts\/9638\/revisions\/9646"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kenes-exhibitions.com\/biomed\/wp-json\/wp\/v2\/media\/9643"}],"wp:attachment":[{"href":"https:\/\/kenes-exhibitions.com\/biomed\/wp-json\/wp\/v2\/media?parent=9638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kenes-exhibitions.com\/biomed\/wp-json\/wp\/v2\/categories?post=9638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kenes-exhibitions.com\/biomed\/wp-json\/wp\/v2\/tags?post=9638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}